Publication:
Recommendations by the Spanish Society of Hospital Pharmacy, the Spanish Society of Oncology Nursing and the Spanish Society of Medical Oncology for the safe management of antineoplastic medication in cancer patients.

dc.contributor.authorVera, R
dc.contributor.authorOtero, M J
dc.contributor.authorAyala de la Peña, F
dc.contributor.authorGonzález-Pérez, C
dc.contributor.authorPeñuelas, Á
dc.contributor.authorSepúlveda, J M
dc.contributor.authorQuer, N
dc.contributor.authorDoménech-Climent, N
dc.contributor.authorVirizuela, J A
dc.contributor.authorBeorlegui, P
dc.contributor.authorGorgas, M Q
dc.date.accessioned2023-01-25T10:23:00Z
dc.date.available2023-01-25T10:23:00Z
dc.date.issued2018-10-08
dc.description.abstractTo define recommendations that permit safe management of antineoplastic medication, minimise medication errors and improve the safety of cancer patients undergoing treatment. By reviewing the literature and consulting the websites of various health organisations and agencies, an expert committee from the Spanish Society of Hospital Pharmacy and the Spanish Society of Medical Oncology defined a set of safe practices covering all stages of providing cancer therapy to patients. The Spanish Society of Oncology Nursing revised and endorsed the final list. In total, 68 recommendations arranged in five sections were defined. They include issues concerning the training of health professionals, the technological resources needed, treatment planning, informing the patient and his/her family, the processes of prescribing, preparing, dispensing and administering cancer therapy (orally, parenterally or intrathecally), assessing patient adherence and treatment toxicity. It is essential for healthcare establishments to implement specific measures designed to prevent medication errors, in order to ensure the safety of cancer patients treated with antineoplastic medication.
dc.identifier.doi10.1007/s12094-018-1945-x
dc.identifier.essn1699-3055
dc.identifier.pmid30298467
dc.identifier.unpaywallURLhttps://link.springer.com/content/pdf/10.1007%2Fs12094-018-1945-x.pdf
dc.identifier.urihttp://hdl.handle.net/10668/13049
dc.issue.number4
dc.journal.titleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
dc.journal.titleabbreviationClin Transl Oncol
dc.language.isoen
dc.organizationHospital Universitario Virgen Macarena
dc.page.number467-478
dc.pubmedtypeJournal Article
dc.pubmedtypePractice Guideline
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAntineoplastic agents
dc.subjectMedication errors
dc.subjectPatient safety
dc.subjectPrevention and control
dc.subjectSafety management organisation and administration
dc.subject.meshAntineoplastic Agents
dc.subject.meshHumans
dc.subject.meshMedical Oncology
dc.subject.meshMedication Errors
dc.subject.meshMedication Therapy Management
dc.subject.meshNeoplasms
dc.subject.meshOncology Nursing
dc.subject.meshPatient Safety
dc.subject.meshPharmacy Service, Hospital
dc.subject.meshSpain
dc.titleRecommendations by the Spanish Society of Hospital Pharmacy, the Spanish Society of Oncology Nursing and the Spanish Society of Medical Oncology for the safe management of antineoplastic medication in cancer patients.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number21
dspace.entity.typePublication

Files